New combo aims to tackle returning blood cancer
NCT ID NCT07024706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs, acalabrutinib and venetoclax, in 80 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after initial treatment. Participants must have responded well to their first therapy and stayed in remission for at least two years. The study aims to see if this finite-duration combo can effectively control the disease again.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib and venetoclax
What this could lead to
If successful, this could offer a new treatment option for people with CLL/SLL whose cancer returns after initial therapy, potentially extending remission without continuous medication.
What could go wrong
This is a small, early-phase study (80 people) with no results yet. The treatment may not work as well as hoped, and side effects like low blood counts or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Horn, 3580, Austria
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Hradec Kralova, 50005, Czechia
-
Research Site
Ostrava, 708 502, Czechia
-
Research Site
Dublin, 7, Ireland
-
Research Site
Dublin, D08 NHY1, Ireland
-
Research Site
Lugo, 48022, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Padua, 35128, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Rome, 00168, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Bydgoszcz, 85-168, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Lodz, 93-513, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Warsaw, 02-172, Poland
-
Research Site
Warsaw, 02-776, Poland
-
Research Site
Barcelona, 08041, Spain
-
Research Site
Barcelona, 8035, Spain
-
Research Site
Granada, 18014, Spain
-
Research Site
Madrid, 28031, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Majadahonda, 28222, Spain